Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1999 Apr;9(2):369-91.
doi: 10.1111/j.1750-3639.1999.tb00233.x.

Diabetic neuropathies: features and mechanisms

Affiliations
Review

Diabetic neuropathies: features and mechanisms

D W Zochodne. Brain Pathol. 1999 Apr.

Abstract

Diabetic neuropathies include both focal neuropathies and diffuse polyneuropathy. Polyneuropathy, the most common of the diabetic neuropathies excluding focal entrapment, has not yet been explained by a single disease mechanism despite intensive investigation. A number of abnormalities appear to cascade into a 'vicious cycle' of progressive microvascular disease associated with motor, sensory and autonomic fiber loss. These abnormalities include excessive polyol (sugar alcohol) flux through the aldose reductase pathway, functional and structural alterations of nerve microvessels, nerve and ganglia hypoxia, oxidative stress, nonspecific glycosylation of axon and microvessel proteins, and impairment in the elaboration of trophic factors critical for peripheral nerves and their ganglia. While an initiating role for nerve ischemia in the development of polyneuropathy has been proposed, the evidence for it can be questioned. The role of sensory and autonomic ganglia in the development of polyneuropathy has had relatively less attention despite the possibility that they may be vulnerable to a variety of insults, particularly neurotrophin deficiency. Superimposed on the deficits of polyneuropathy is the failure of diabetic nerves to regenerate as effectively as nondiabetics. Polyneuropathy has not yet yielded to specific forms of treatment but a variety of new trials addressing plausible hypotheses have been initiated. This review will summarize some of the clinical, pathological and experimental work applied toward understanding human diabetic neuropathy and will emphasize ideas on pathogenesis.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ahlgren SC, Levine JD. (1994) Protein kinase C inhibitors decrease hyperalgesia and C‐fiber hyperexcitability in the streptozotocin‐diabetic rat. J Neurophysiol 72(2):684–692. - PubMed
    1. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. (1995) Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 113(12):1538–1544. - PubMed
    1. Aldskogius H, Northrup JM, Keyt BA, et al. (1992) Axotomy‐induced changes in primary sensory neurons. In: Sensory Neurons. Diversity development and plasticity. Scott SA., (Eds.) pp. 363–383, Oxford University Press. Oxford .
    1. Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. (1994) Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 634(1):7–12. - PubMed
    1. Arvidson B. (1979) Distribution of protein tracers in peripheral ganglia. Acta Univ Ups 344:1–72. - PubMed

Publication types

MeSH terms